Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their ...

SGMC Health has successfully performed its first robotic-assisted lung biopsy using the state-of-the-art Ion robot. The health system said the procedure marked a major advancement in lung cancer ...

Imagene's AI-based multigene panel for predicting non-small cell lung cancer biomarkers from biopsy images will be combined with Tempus' real-world data.

BENGALURU: When 52-year-old Rahul (name altered), a non-smoker and fitness enthusiast, started experiencing a persistent cough, he initially thought it was a se ...

Collaboration focuses on launching an AI-powered biomarker prediction panel targeting actionable biomarkers to revolutionize lung cancer diagnostics and enable commercialization of a diagnostic panel.

Among patients with stage IA non-small cell lung cancer, long-term survival was better with lobectomy or segmentectomy vs.

Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80 to 85% of all cases of lung cancer. There are different stages of NSCLC, ranging from 0 to 4; ...

Small cell lung cancer (SCLC) accounts for about 15% of lung cancer cases and is categorized into limited and extensive stages. Treatment options include radiation, chemotherapy, and immunotherapy ...

It has been recommended as an additional treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) by the National Institute for ...